Beltone’s Midcap Fund Buys 25% Of Bio-Pharma

The Managing Director of Beltone Private Equity told Al-Mal daily that the company’s “Midcap Fund” finalized acquiring 25.0% of Bio-Pharma Egypt at a total value of EGP 10.0 million. He added that Bio-Pharma’s paid-in capital was doubled to reach EGP 10.0 million.

This increase will be used in pursuing expansions through raising production capacity and launching new products.

It is worth noting that Beltone Private Equity is a subsidiary of Beltone Financial Holding.

Mubasher